Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

This review identified 126 commercially available antibodies approved globally between
1986 and February 2021 including 10 antibody drug conjugates, 16 biosimilars, and 3 …

Background Patients with refractory hypercholesterolemia, who have high low-density
lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at …

Background & aims This study compared pharmacokinetics, symptomatic and endoscopic
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …

Background Intravenous daratumumab for treatment of patients with multiple myeloma
involves a lengthy infusion that affects quality of life, and infusion-related reactions are …

Embedding microfluidic architectures with microneedles enables fluid management
capabilities that present new degrees of freedom for transdermal drug delivery. To this end …

Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for
one third of the total approved mAbs, are formulated with high protein concentration (100 …

Nanotechnological drug delivery platforms represent a new paradigm for cancer
therapeutics as they improve the pharmacokinetic profile and distribution of …

With the rapid development of biomaterials and biotechnologies, various functional
materials-based drug delivery systems (DDS) are developed to overcome the limitations of …